Dear Fellow Stockholders,With my inaugural letter to stockholders, I am pleased to provide an update on our recent initial public offering ("IPO"), share our mission, outline the current status of our development
Chromocell Therapeutics Corporation (NYSE:CHRO) ("Chromocell" or the "Company"), a clinical-stage biotech company focused on developing and commercializing new, non-opioid therapeutics to alleviate pain, today announced